HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: In 2006, the FDA first approved the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) to treat cutaneous T-cell lymphoma (CTCL)[49].